Holmusk's NeuroBlu Now Accessing 46 Million Patients with Comprehensive Neurology and Behavioral Health Insights
Holmusk's NeuroBlu Expansion: A New Era in Neurological and Behavioral Health Research
Holmusk, a leading healthcare data science company, has announced a significant enhancement to its NeuroBlu platform, now encompassing over 46 million de-identified patient records. This impressive expansion marks an increase of more than 5 million patients and integrates key datasets from two top-tier neurology health systems, emphasizing the platform's commitment to providing robust longitudinal data in the field of neurology and behavioral health.
The recent update, labeled as NeuroBlu 26R2, signifies not just an increase in patient numbers, but a shift towards a more comprehensive research-grade signal that blends neurological and behavioral health data within the same records. This is vital as it aligns with contemporary strategies for understanding the interplay of mental health and neurological conditions.
Building a Comprehensive Data Ecosystem
NeuroBlu's latest growth is anchored chiefly by two distinguished health systems ranked by U.S. News & World Report, ensuring that the data reflects both regional representation and care quality. These additions solidify the platform's geographic diversity and integration across various care settings, from community clinics to specialized neurology programs, providing a holistic view of patient journeys.
An essential feature of NeuroBlu is its linkage-ready longitudinal EHR data, facilitated through the DataVant ecosystem, which empowers life sciences organizations to merge their datasets with claims data. This capability offers a broader perspective on patients' healthcare pathways across multiple care environments and payer systems.
Depth of Neurological Data
In its current iteration, NeuroBlu 26R2 excels in delivering substantive, longitudinal data across various neurological conditions:
- - Alzheimer's Disease (AD): 520K patients
- - Mild Cognitive Impairment (MCI): 428K patients
- - Dementia: 2.1M patients
- - Parkinson's Disease: 324K patients
- - Epilepsy: 829K patients
- - Migraine: 2.7M patients
- - Sleep Disorders: 2.1M patients
- - Pain Disorders: 23.9M patients
Moreover, trends in biomarker data, particularly for Alzheimer’s research, indicate a growing repository of clinically relevant information. NeuroBlu 26R2 has structured its biomarker assessments, with over 4,600 documented occurrences of tau assays and 32,000 biomarker-linked records, providing a rich resource for clinical trials focusing on treatment efficacy and disease progression.
Attention to Behavioral Health Comorbidity
One of the defining characteristics of NeuroBlu is its ability to capture both neurological and behavioral health conditions within singular longitudinal records. In total, 41% of patients, nearly 19 million, exhibit diagnoses spanning both health realms, thereby supporting rigorous research into comorbidities like depression, anxiety, and cognitive impairments in conjunction with neurological disorders. This integration supports the development of treatment protocols tailored to the complexities of dual diagnoses, providing invaluable information for pharmaceutical and biotechnology companies involved in research and clinical trials.
Future Directions for NeuroBlu
The NeuroBlu platform not only aims to facilitate ongoing research but encourages organizations with specific data needs to engage proactively. Holmusk is poised to partner with the pharmaceutical sector by providing detailed data specifications and accommodating requests for tailored analyses. With anticipated future expansions in neuroimaging data and enhanced clinical insights, NeuroBlu stands at the forefront of innovation in healthcare data applications.
Conclusion
Holmusk’s NeuroBlu represents a transformative step in utilizing health data science for neurological and behavioral health insights. By leveraging extensive patient records and integrating vast datasets, Holmusk continues to support evidence generation pertinent to the life sciences industry, paving the way for deeper understanding and better treatment options for patients across various neurological domains. This commitment to data-driven healthcare solutions places Holmusk and NeuroBlu in a unique position to lead advancements in medical research and patient care.
For more information and to explore the NeuroBlu platform, please visit Holmusk's website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.